Skip to content

Michael Vincent Meluzio, VP, Prin. Accounting Officer at Cue Biopharma, sold CUE on Aug 13, 2026

Data as of Oct 16

▼ SELL$125K4,106 shares at $30.35Michael Vincent Meluzio VP, Prin. Accounting OfficerCUE Cue Biopharma, Inc.
Watch CUE
Traded
Aug 13, 2026
Disclosed
Aug 17, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Michael Vincent Meluzio, VP, Prin. Accounting Officer at Cue Biopharma, sold CUE on Aug 13, 2026TRADEDDISCLOSED
CUESimilar stocks (XLV — its sector index fund), rebased to CUE's price on the disclosure day
CUE since disclosure
−39.5%
after the sale
Similar stocks (XLV) since disclosure
+5.8%
XLV — its sector index fund

Change in closing price from Aug 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLMichael Vincent Meluzio VP, Prin. Accounting OfficerCUE Cue Biopharma, Inc.$44.6Kdisclosed Aug 17 · filed 4 days after the trade
  2. ▼ SELLMichael Vincent Meluzio VP, Prin. Accounting OfficerCUE Cue Biopharma, Inc.$93disclosed Aug 17 · filed 4 days after the trade

See every trade on CUE →